Aspira Women's Health (AWH) 10-K 13 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 09, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	VERMILLION, INC.
Entity Central Index Key	926,617
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 56,898,624
Entity Common Stock, Shares Outstanding		60,039,338

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 5,539,000	$ 5,242,000
Accounts receivable	205,000	275,000
Prepaid expenses and other current assets	459,000	498,000
Inventories	102,000	93,000
Total current assets	6,305,000	6,108,000
Property and equipment, net	1,181,000	1,911,000
Other assets	11,000
Total assets	7,497,000	8,019,000
Current liabilities:
Accounts payable	745,000	881,000
Accrued liabilities	1,650,000	1,464,000
Short-term debt	185,000	182,000
Other current liabilities	29,000	34,000
Total current liabilities	2,609,000	2,561,000
Non-current liabilities:
Long-term debt	1,481,000	1,667,000
Other non-current liabilities		29,000
Total liabilities	4,090,000	4,257,000
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at December 31, 2017 and 2016
Common stock, $0.001 par value, 150,000,000 shares authorized; 60,036,017 and 52,328,492 shares issued and outstanding at December 31, 2017 and 2016, respectively	60,000	52,000
Additional paid-in capital	399,400,000	389,266,000
Accumulated deficit	(396,053,000)	(385,556,000)
Total stockholders' equity	3,407,000	3,762,000
Total liabilities and stockholders' equity	$ 7,497,000	$ 8,019,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	60,036,017	52,328,492
Common stock, shares outstanding	60,036,017	52,328,492

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue:
Product	$ 2,853	$ 2,320
Service	268	322
Total revenue	3,121	2,642
Cost of revenue:
Product	1,756	1,974
Service	1,158	724
Total cost of revenue	2,914	2,698
Gross profit / (loss)	207	(56)
Operating expenses:
Research and development	837	2,172
Sales and marketing	4,268	6,798
General and administrative	5,543	5,928
Total operating expenses	10,648	14,898
Loss from operations	(10,441)	(14,954)
Interest (expense) income, net	(42)	(28)
Other (expense) / income, net	(14)	14
Net loss	(10,497)	(14,968)
Deemed dividend on warrant repricing	(942)
Net loss attributable to common stockholders	$ (11,439)	$ (14,968)
Net loss per share attributable to common stockholders - basic and diluted	$ (0.20)	$ (0.29)
Weighted average common shares used to compute basic and diluted net loss per common share	56,943,596	52,197,969

Consolidated Statements Of Ope5

Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cost Of Revenue [Member]
Stock-based compensation expense	$ 136	$ 115
Research And Development [Member]
Stock-based compensation expense	9	71
Sales And Marketing [Member]
Stock-based compensation expense	160	108
General And Administrative [Member]
Stock-based compensation expense	$ 1,134	$ 885

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance (in shares) at Dec. 31, 2015	52,113,059
Balance at Dec. 31, 2015	$ 52	$ 388,082	$ (370,588)	$ 17,546
Net loss			(14,968)	$ (14,968)
Common stock issued in conjuntion with exercise of stock options (in shares)	3,541			3,541
Common stock issued in conjuntion with execise of stock options		5		$ 5
Common stock issued for restricted stock awards (in shares)	211,892
Common stock issued for restricted stock awards		334		334
Stock compensation charge		845		845
Balance (in shares) at Dec. 31, 2016	52,328,492
Balance at Dec. 31, 2016	$ 52	389,266	(385,556)	3,762
Net loss			(10,497)	(10,497)
Common stock and warrants issued in conjunction with private placement sale, net of issuance costs (in shares)	3,747,125
Common stock and warrants issued in conjunction with private placement sale, net of issuance costs	$ 4	5,123		5,127
Common stock issued in conjunction with exercise of warrants, net of issuance costs (in shares)	3,796,818
Common stock issued in conjunction with exercise of warrants, net of issuance costs	$ 4	3,572		3,576
Common stock issued for restricted stock awards (in shares)	163,582
Common stock issued for restricted stock awards		335		335
Stock compensation charge		1,104		1,104
Balance (in shares) at Dec. 31, 2017	60,036,017
Balance at Dec. 31, 2017	$ 60	$ 399,400	$ (396,053)	$ 3,407

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (10,497,000)	$ (14,968,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	786,000	723,000
Stock-based compensation expense	1,439,000	1,179,000
Loss on sale and disposal of property and equipment	4,000	6,000
Changes in operating assets and liabilities:
Accounts receivable	70,000	(188,000)
Prepaid expenses and other assets	28,000	142,000
Inventories	(9,000)	(6,000)
Accounts payable, accrued liabilities and other liabilities	50,000	(851,000)
Net cash used in operating activities	(8,129,000)	(13,963,000)
Cash flows from investing activities:
Purchase of property and equipment	(60,000)	(1,261,000)
Net cash used in investing activities	(60,000)	(1,261,000)
Cash flows from financing activities:
Proceeds from private placement offering of common stock and warrants, net of issuance costs	5,127,000
Proceeds from exercise of common stock warrants, net of issuance costs	3,576,000
Proceeds from issuance of DECD loan, net of issuance costs		1,967,000
Principal repayment of DECD loan	(183,000)	(118,000)
Repayment of capital lease obligations	(34,000)	(30,000)
Proceeds from issuance of common stock from exercise of stock options		5,000
Net cash provided by financing activities	8,486,000	1,824,000
Net increase / (decrease) in cash and cash equivalents	297,000	(13,400,000)
Cash and cash equivalents, beginning of year	5,242,000	18,642,000
Cash and cash equivalents, end of year	5,539,000	5,242,000
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	47,000	38,000
Supplemental disclosure of non-cash investing and financing activities:
Deemed dividend on warrant repricing	$ 942,000

Basis Of Presentation And Summa

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies	12 Months Ended
	Dec. 31, 2017
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies [Abstract]
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies	NOTE 1: Basis of Presentation and Summary of Significant Accounting and Reporting Policies Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells the OVA1™ and Overa™ risk of malignancy tests for ovarian cancer (“OVA1” and “Overa”). Until August 2015, the Company distributed OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”) (see Note 3). Since August 2015, the Company has distributed all tests through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”). The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which was formed in April 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. ASPiRA IVD was built around a core of laboratory expertise and a United States Food and Drug Administration (“FDA”)-compliant quality system, and strives to deliver accurate and reliable results to its third-party customers suitable for FDA submission.  Liquidity As discussed in Note 6, on March 22, 2016, the Company entered into a loan agreement , as amended (the “Loan Agreement”) , pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (“DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty. On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. Aggregate gross proceeds of the private placement were approximately $5,597,000 ( approximately $5,127,000 net of transaction costs) . The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share. The warrants expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period . In December 2014, the Company issued warrants to purchase up to an aggregate of 4,166,659 shares of Vermillion common stock at an exercise price of $2.00 per share in conjunction with a December 2014 private placement of Vermillion common stock. The warrants would have expire d by their original terms on December 23, 2017. On August 31, 2017, certain holders exercised warrants to purchase 3,796,818 shares of Vermillion common stock in consideration for the Company agreeing to reduce the exercise price to $1.00 per share of Vermillion common stock. The Company issued 3,796,818 shares of Vermillion common stock and received $3,796,818 in aggregate gross proceeds (approximately $3,576,000 net of transaction costs). The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $396,053,000 at December 31, 2017. The Company expects to incur a net loss in 2018 as well. The Company’s management believes that successful achievement of the business objectives will require additional financing. The Company expects to raise capital through a variety of sources, which may include the exercise of common stock warrants, public and private equity offerings, debt financing, collaborations, licensing arrangements, grants and government funding and strategic alliances. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the business, results of operations and financial condition. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Management expects cash from product and ASPiRA IVD sales to be the Company’s only material, recurring source of cash in 2018. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation .  Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates.  Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.  Fair Value Measurement Accounting Standards Codification (“ASC”) Topic 820, Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.  Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 , but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.  Accounts receivable Virtually all accounts receivable are derived from sales made to customers located in North America. The Company performs ongoing credit evaluations of its customer’s financial condition and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable. Accounts receivable at December 31, 2017 was from 20 customers. Accounts receivable at December 31, 2016 was from 16 customers.  Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.  Revenue Recognition Product Revenue: The Company has adopted ASC 954-605, Health Care Entities—Revenue Recognition, as revenue from laboratory services has become significant to the Company . The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1 and Overa tests may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.  Estimates of amounts that the Company will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the patient’s health plan. Some payers may not cover the OVA1 or Overa test as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.  Service Revenue: The Company’s service revenue is generated by performing IVD trial services for third-party customers. In accordance with SEC Staff Accounting Bulletin Topic 13, service revenue is recognized when the following revenue recognition criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  Research and Development Costs Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.  Patent Costs Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately $258,000 and $308,000 for the years ended December 31, 2017 and 2016, respectively.  Stock-Based Compensation The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Amended and Restated 2010 Stock Incentive Plan, as amended (the “2010 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. The Company uses the straight line method to amortize the fair value over the vesting period of the award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment. The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility is estimated using Company historical volatility in deriving the expected volatility assumption . The Company made an assessment that Company historic volatility is most representative of future stock price trends. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of the Company’s common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company uses the straight-line method to amortize the fair value over the vesting period of the award. The Company records stock-based compensation net of estimated forfeitures . The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options is recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another.  Contingencies The Company accounts for contingencies in accordance with ASC 450 Contingencies ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.  Income Taxes The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. ASC Topic 740, Accounting for Uncertainty in Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets. New tax legislation, commonly referred to as the Tax Cuts and Jobs Act (H.R. 1), was enacted on December 22, 2017. ASC740, Accounting for Income Taxes , requires companies to recognize the effect of tax law changes in the period of enactment even though the effective date for most provisions is for tax years beginning after December 31, 2017. Since our federal deferred tax asset was fully offset by a valuation allowance, the reduction in the U.S. corporate income tax rate to 21% did not materially affect our financial statements. Significant provisions that are not yet effective but may impact income taxes in future years include: the repeal of the corporate Alternative Minimum Tax, the limitation on the current deductibility of net interest expense in excess of 30% of adjusted taxable income for levered balance sheets, a limitation on utilization of net operating losses generated after tax year 2017 to 80% of taxable income, the unlimited carryforward of net operating losses generated after tax year 2017, temporary 100% expensing of certain business assets, additional limitations on certain general and administrative expenses, and changes in determining the excessive compensation limitation. Currently, we do not anticipate paying cash federal income taxes in the near term due to any of the legislative changes, primarily due to the availability of our net operating loss carryforwards. Future interpretations relating to the recently enacted U.S. federal income tax legislation which vary from our current interpretation and possible changes to state tax laws in response to the recently enacted federal legislation may have a significant effect on this projection.  Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.  Fair Value of Financial Instruments Financial instrument s include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt are at cost, which approximates fair value due to the short maturity of those instruments.  Segment Reporting The Company operates one reportable segment.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2017
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	 NOTE 2: Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update changes the impairment model from the currently used incurred loss methodology to an expected loss methodology, which will result in the more timely recognition of losses. The ASU is scheduled to be effective in 2020. The Company is currently assessing the impact of this ASU on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently in the early stages of evaluating the impact of the pending adoption of the new standard on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The Company adopted the new revenue recognition standard as of January 1, 2018 using the modified retrospective method. The Company has completed its analysis of the effect ASU 2014-09 will have on its Service Revenue and believes that the adoption of ASU 2014-09 will not result in a material cumulative catch-up adjustment under the modified retrospective method, or have a material impact on the Company's financial position or results of operations. The Company has also substantially completed its analysis of the effect ASU 2014-09 will have on its Product Revenue . However, the Company is continuing to analyze data as there is a long collection cycle on some accounts and thus the passage of time provides more accurate data for analysis. Revenue that was recognized upon the ultimate receipt of cash under the Company’s previous revenue recognition policy has be en reassessed under the new standard and will now be recognized upon performance of the OVA1 or Overa test . The Company also review ed its patient account population to determine the appropriate distribution of patient accounts by payer ( i.e. , Medicare, patient pay, other third-party payer, etc .) into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on a contract-by-contract basis. The Company has estimated that a cumulative effect adjustment of approximately $400,000 to $700,000 will be recognized as of January 1, 2018 to beginning accumulated deficit and accounts receivable to reflect the recognition of revenue from accounts previously recognized on the cash basis of accounting.   

Strategic Alliance And Secured

Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated	12 Months Ended
	Dec. 31, 2017
Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated [Abstract]
Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated	NOTE 3: Strategic Alliance And Secured Line Of Credit with Quest Diagnostics Incorporated In March 2015, the Company reached an agreement with Quest Diagnostics that terminated the previous Strategic Alliance Agreement with Quest Diagnostics. The Company also entered into a commercial agreement with Quest Diagnostics. Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 2015. Pursuant to this agreement, as amended as of March 1, 201 8 , Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 201 9 in exchange for a market value fee. Per the terms of the new commercial agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers.  

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2017
Property And Equipment [Abstract]
Property And Equipment	Note 4: Property and Equipment T he components of property and equipment as of December 31, 201 7 and 201 6 were as follo ws :     December 31,  (in thousands) 2017 2016  Machinery and equipment $ 1,400 $ 1,381  Demonstration equipment 39 39  Computer equipment and software 1,055 1,029  Furniture and fixtures 120 127  Leasehold improvements 706 704  Gross property and equipment 3,320 3,280  Accumulated depreciation and amortization (2,139) (1,369)  Property and equipment, net $ 1,181 $ 1,911  Depreciation expense for property and equipment was $786,000 and $723,000 for the years ended December 31, 2017 and 2016, respectively. The accumulated amortization of assets under capital lease obligations was $193,000 and the net book value of assets under capital lease obligations was $39,000 as of December 31, 2017. The accumulated amortization of assets under capital lease obligations was $116,000 and the net book value of assets under capital lease obligations was $116,000 as of December 31, 2016.

Accured Liabilities

Accured Liabilities	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities [Abstract]
Accrued Liabilities	NOTE 5 : Accrued Liabilities The components of accrued liabilities as of December 31, 2017 and 20 16 were as follows:      December 31,  (in thousands) 2017 2016  Payroll and benefits related expenses $ 867 $ 541  Collaboration and research agreements expenses 358 414  Professional services 216 217  Tax-related liabilities - 4  Other accrued liabilities 209 288  Total accrued liabilities $ 1,650 $ 1,464 

Commitments, Contingencies And

Commitments, Contingencies And Debt	12 Months Ended
	Dec. 31, 2017
Commitments, Contingencies And Debt [Abstract]
Commitments, Contingencies And Debt	NOTE 6: Commitments , Contingencies and debt As of December 31, 2017, the annual amounts of future minimum payments under certain of the Company’s contractual obligations were :      Payments Due by Period  (in thousands) Total Less Than 1 Year 1-3 Years 3-5 Years More Than 5 Years  Operating Leases $ 574 $ 258 $ 261 $ 55 $ -  Capital Leases 20 20 - - -  Debt Obligations 1,860 221 442 442 755  Total Contractual Obligations $ 2,454 $ 499 $ 703 $ 497 $ 755   In addition, the Company has minimum royalty obligations (described below in non-cancelable collaboration obligations and other commitments) and minimum quantities of reagent purchases from the manufacturer of certain laboratory instruments.  Development L oan On March 22, 2016, the Company entered into the Loan Agreement with the DECD, pursuant to which the Company may borrow up to $4,000,000 from the DECD. Proceeds from the loan were utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company’s Trumbull, Connecticut facility and operations. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026 . As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender. Under the terms of the Loan Agreement, as amended, the Company may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by March 1, 2021 (the “Measurement Date”). Conversely, if the Company is either unable to meet these job creation and retention milestones, namely, hiring and retaining for a consecutive two-year period 40 full-time employees with a specified average annual salary by the Measurement Date and retaining those employees for a two year period or does not maintain the Company’s Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5% of the total funded l oan . An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement . The Agreement provides that the remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty . The balance of the DECD loan was $1,666,000 and $1,849,000 at December 31, 2017 and 2016 , respectively .  Operating Leases The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease, including its principal facility and CLIA laboratory located in Austin, Texas. As of December 31, 2017 the Company’s Austin, Texas lease included an annual base rent of $86,000 and annual estimated common area charges, taxes and insurance of $46,000 . The lease expires on January 31, 2019 . The Company’s Trumbull, Connecticut lease includes an aggregate annual base rent of $32,000 and annual estimated common area charges, taxes and insurance of $95,000 . The lease expires on June 8, 2021 . Rental expense under operating leases for the years ended December 31, 201 7 and 201 6 totaled $254,000 and $234,000 , respectively.  Capital Lease In April 2015, the Company leased a laboratory instrument for a total initial payment of $125,000 and ongoing payments of approximately $3,500 per month for 36 months after delivery. The agreement also requires minimum annual purchases of reagents from the manufacturer of the equipment. The laboratory instrument was placed into service on July 1, 2015. The accumulated amortization of assets under capital lease obligations was $193,000 and the net book value of assets under capital lease obligations was $39,000 as of December 31, 201 7 . The accumulated amortization of assets under capital lease obligations was $116,000 and the net book value of assets under capital lease obligations was $116,000 as of December 31, 201 6 .  Non - cancelable Collaboration Obligations and Other Commitments The Company ha d a research collaboration agreement with The Johns Hopkins University School of Medicine (“JHU”) directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human diseas e . This agreement expired on March 31, 2016. Collaboration expenses under the JHU collaboration were $15,000 and $264,000 for the years ended December 31, 201 7 and 201 6 , respectively. Collaboration expenses under the JHU collaboration are included in research and development expenses. In addition, under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500 . R oyalty expense for the years ended December 31, 201 7 and 201 6 totaled $116,000 and $92,000 , respectively.  Contingent Liabilities F rom time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations. The Company establish es reserves for specific liabilities in connection with legal actions that management deem s to be probable and estimable. The Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company’s financial position or results of operations.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2017
Common Stock [Abstract]
Common Stock	NOTE 7: Common Stock 2017 Private Placement On February 17, 2017 , the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. Net proceeds of the private placement were approximately $5,127 ,000 after deducting offering expenses. The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share . The warrants may be exercised from time to time beginning August 17, 2017 and expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period . The sale of common stock and issuance of warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is $804,000 and to the common stoc k is approximately $ 4,323 ,000 .  Warrants Warrants outstanding as of December 31, 201 7 and 201 6 were as follows:     Exercise Price Number of Shares Outstanding under Warrant  Issuance Date Expiration Date per Share December 31, 2017 December 31, 2016  December 23, 2014 December 23, 2017 $ 2.00 - 4,166,659  February 17, 2017 February 17, 2022 $ 1.80 2,810,338 -  2,810,338 4,166,659   

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2017
Loss Per Share [Abstract]
Loss Per Share	 NOTE 8 : Loss Per Share The reconciliation of the numerators and denominators of basic and diluted loss per share for the years ended December 31, 2017 and 2016 was as fol lows :    Loss Shares Per Share  (In thousands, except per share data) (Numerator) (Denominator) Amount  Year ended December 31, 2016:  Net loss available to common shareholders - basic $ (14,968) 52,197,969 $ (0.29)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (14,968) 52,197,969 $ (0.29)   Year ended December 31, 2017:  Net loss $ (10,497)  Deemed dividend on warrant repricing (942)  Net loss available to common shareholders - basic (11,439) 56,943,596 $ (0.20)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (11,439) 56,943,596 $ (0.20)   Due to net losses for the years ended December 31, 2017 and 2016, diluted loss per share is calculated using the weighted average number of common shares outstanding and excludes the effects of potential shares of common stock that are antidilutive. The potential shares of common stock that have been excluded from the diluted loss per share calculation above for the years ended December 31, 2017 and 2016 were as follows:     Year Ended December 31,  2017 2016  Stock options 4,219,568 3,451,073  Stock warrants 2,810,338 4,166,659  Unvested restricted stock awards 1,704 7,752  Potential common shares 7,031,610 7,625,484 

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2017
Employee Benefit Plans [Abstract]
Employee Benefit Plans	 NOTE 9: Employee Benefit Plans 2000 Stock Plan Under the Amended and Restated 2000 Stock Plan (the “2000 Plan”), options could be granted at prices not lower than 85% and 100% of the fair market value of the common stock for non-statutory and statutory stock options, respectively. Options generally vest monthly over a period of four years and unexercised options generally expire ten years from the date of grant. The authority of Vermillion’s Board of Directors to grant new stock options and awards under the 2000 Plan terminated in 2010. There were no stock options under the 2000 Stock Plan exercised during the year ended December 31, 2017 or 2016. No additional shares of common stock were reserved for future option grants under the 2000 Plan.  2010 Stock Incentive Plan Under the 2010 Plan, employees, directors and consultants of the Company are eligible to receive awards. The 2010 Plan is administered by the Compensation Committee of Vermillion ’s Board of Directors. The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. I n June 2015 , Vermillion ’s stockholders approved an increase of 4,500,000 in the number of shares available for issuance under the 2010 Plan for a total of 8,122,983 shares. Unexercised options generally expire ten years from the date of grant. There were no options exercised during the year ended December 31, 2017. Options to purchase 3,541 shares of common stock were exercised during the year ended December 31, 201 6 . During the year ended December 31, 201 7 , Vermillion issued to Vermillion ’s Board of Directors 131,250 shares of restricted stock under the 2010 Plan having a fair value of $281,000 as payment for services rendered in 201 7 . The Company also issued to certain consultants 32,332 shares of restricted stock under the 2010 Plan having a fair value of $5 4 ,000 . During the year ended December 31, 201 6 , Vermillion issued to Vermillion ’s Board of Directors 197,727 shares of restricted stock under the 2010 Plan having a fair value of $310,000 as payment for services rendered in 201 6 . The Company also issued to certain consultants 14,165 shares of restricted stock under the 2010 Plan having a fair value of $18,000 .  The activity related to shares available for grant under the 2000 Plan and the 2010 Plan for the years ended December 31, 201 7 and 201 6 was as follows:     2000 Stock Plan 2010 Stock Option Plan Total  Shares available at December 31, 2015 - 3,371,505 3,371,505  Options canceled 33,050 2,243,217 2,276,267  Reduction in shares reserved (33,050) - (33,050)  Options granted - (2,413,070) (2,413,070)  Restricted stock units granted - (211,892) (211,892)  Shares available at December 31, 2016 - 2,989,760 2,989,760  Options canceled 3,050 776,455 779,505  Reduction in shares reserved (3,050) - (3,050)  Options granted - (1,548,000) (1,548,000)  Restricted stock units granted - (163,582) (163,582)  Shares available at December 31, 2017 - 2,054,633 2,054,633   The stock option activity under the 2000 Plan and 2010 Plan for the years ended December 31, 201 7 and 201 6 was as follows:    Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term  Options outstanding at December 31, 2015 3,317,811 $ 2.29 $ 91 8.24  Granted 2,413,070 1.33  Exercised (3,541) 1.30  Canceled (2,276,267) 2.21  Options outstanding at December 31, 2016 3,451,073 $ 1.70 $ 41 8.46  Granted 1,548,000 2.05  Exercised - -  Canceled (779,505) 1.51  Options outstanding at December 31, 2017 4,219,568 $ 1.86 $ 1,033 8.02   Shares exercisable:  December 31, 2017 1,855,662 $ 1.99 $ 427 7.06  Shares expected to vest:  December 31, 2017 1,938,403 $ 1.77 $ 606 8.77   The range of exercise prices for options outstanding and exercisable at December 31, 201 7 is as follows:     Exercise Price Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Life in Years Options Exercisable Weighted Average Exercise Price  $ 0.01 - $ 1.30 435,625 $ 0.99 8.74 188,489 $ 1.00  1.31 - 1.64 1,369,168 1.50 8.01 561,957 1.52  1.65 - 2.08 1,038,500 1.96 7.44 660,131 1.95  2.09 - 11.55 1,376,275 2.43 8.23 445,085 3.05   $ 0.01 - $ 11.55 4,219,568 $ 1.86 8.02 1,855,662 $ 1.99      (in thousands) Total Intrinsic Value of Options Exercised Total Fair Value of Vested Options  Year ended December 31, 2017 $ - $ 2,272  Year ended December 31, 2016 $ 1 $ 1,562   Stock-based Compensation Employee Stock-based Compensation Expense The Company records stock-based compensation net of estimated forfeitures . The assumptions used to calculate the fair value of options granted under the 2010 Plan that were incorporated in the Black-Scholes pricing model for the years ended December 31, 201 7 and 201 6 were as follows:      Year Ended December 31,  2017 2016  Dividend yield - % - %  Volatility 69 % 77 %  Risk-free interest rate 1.77 % 0.96 %  Expected lives (years) 4.0 4.0  Weighted average fair value $ 1.11 $ 0.77  The allocation of employee stock-based compensation expense by functional area for the years ended December 31, 201 7 and 201 6 was as follows:     Year Ended December 31,  (in thousands) 2017 2016  Cost of sales $ 82 $ 93  Research and development 6 71  Sales and marketing 150 101  General and administrative 914 759  Total $ 1,152 $ 1,024  As of December 31, 201 7 , total unrecognized compensation cost related to un vested stock option awards was approximately $ 2,147 ,000 and the related weighted average period over which it is expected to be recognized was 2. 56 years. 401(k) Plan The Company’s 401(k) Plan allows eligible employees to defer up to an annual limit of the lesser of 90.0% of eligible compensation or a maximum contribution amount subject to the Internal Revenue Service annual contribution limit. The Company is not required to make contributions under the 401(k) Plan. During the years ended December 31, 2017 and 2016 , the Company did not contribute to the 401(k) Plan.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Taxes [Abstract]
Income Taxes	NOTE 10: Income Taxes There was no income tax expense or benefit for the years ended December 31, 201 7 or 201 6 because of net losses during those years. These net losses were generated from domestic operations.  Based on the available objective evidence and uncertainty about the timing and amount of any future profits, the Company has provided a full valuation allowance against our net deferred tax assets at December 31, 201 7 and 201 6 . The components of net deferred tax assets at December 31, 201 7 and 201 6 were as follows:      Year Ended December 31,  (in thousands) 2017 2016  Deferred tax assets:  Net operating losses $ 17,768 $ 22,861  Amortization - R&D intangibles 3,091 5,327  Other 2,461 2,903  Total deferred tax assets 23,320 31,091  Valuation allowance (23,320) (31,091)  Deferred tax assets $ - $ -   Deferred tax liabilities:  Other $ - $ -  Deferred tax liabilities $ - $ -   Net deferred tax asset $ - $ -   The reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 201 7 and 201 6 was as follows:      Year Ended December 31,  2017 2016  Tax at federal statutory rate 34 % 34 %  State tax, net of federal benefit 1 1  Valuation allowance 74 291  Change in warrant valuation - -  Net operating loss and credit reduction due to section 382 limitations - (327)  Permanent items (2) (2)  Change in Federal Tax Rate (2017 Tax Reform) (111) -  Other 4 3  Effective income tax rate - % - %  As of December 31, 201 7 , the Company had pre-tax net operating loss carryforwards of approximately $71,000,000 for federal and $173,000,000 for state tax purposes. If not utilized, these carryforwards begin to expire in 2027 for federal purposes and 2018 for state purposes. In 201 8 , approximately $12,000,000 of the Company’s state net operating loss will expire. As of December 31, 20 16 , we had a net operating loss of approximately $59,000,000 for federal and $167,000,000 for state tax purposes. The Company’s ability to use net operating loss and tax credit carryforwards may be restricted due to ownership change limitations, as required by Section 382 of the Internal Revenue Code of 1986, as amended (“Section 382”), as well as similar state provisions. These ownership changes may also limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. We believe that Section 382 ownership changes occurred as a result of our follow-on public offerings in 2011, 2013 and 2015. Any limitation may result in the expiration of a portion of the net operating loss and credit carryforwards before utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of our valuation allowance . Due to the existence of a valuation allowance, it is not expected that such limitations, if any, will have an impact on our results of operations or financial position. The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. The Act reduces the U.S. federal corporate tax rate from 35 percent to 21 percent. In the year ended December 31, 2017, the Company revised its estimated annual effective rate to reflect a change in its U.S. federal statutory rate from 34 percent to 21 percent. The rate change is effective on January 1, 2018; therefore, the Company’s U.S. statutory tax rate for the fiscal year ended December 31, 2018, will be 21 percent. At December 31, 2017, the Company has not completed its accounting for the tax effects of enactment of the Act; however, in certain cases, as described below, the Company has made a reasonable estimate of the effects on existing deferred tax balances. In other cases, the Company has not been able to make a reasonable estimate and continues to account for those items based on existing accounting under ASC 740, Income Taxes, and the provisions of the tax laws that were in effect immediately prior to enactment. The Securities and Exchange Commission has issued guidance that allows for a measurement period of up to one year after the enactment date of the Act to finalize the recording of the related tax impacts. The final transitional impacts of the Act may differ from the initial estimates.  Provisional amounts  Deferred tax assets and liabilities: Certain domestic-related deferred tax assets and liabilities were remeasured based on the rates at which they are expected to reverse in the future, which is generally 21 percent. As a valuation allowance is recorded for the full amount of these deferred tax assets and liabilities, the remeasurement of the deferred tax assets and liabilities was offset by a corresponding remeasurement of the valuation allowance. We believe that it is more likely than not that the benefit from certain deferred tax assets will not be realized due to the h istory of our operating losses. In recognition of this risk, we have provided a valuation allowance on the deferred tax assets relating to these assets. The valuation allowance was $23,000,000 and $31,000,000 at December 31, 201 7 and 201 6 , respectively. The de crease of $8,000,000 between 201 7 and 201 6 is primarily due to adjustments to the domestic deferred tax assets related to the net operating losses and the change in the federal income tax rate from 34% to 21% under the Act . The Company files income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 201 7 , the Company’s federal returns for the years ended 201 4 through the current period and most state returns for the years ended 201 3 through the current period are still open to examination. In addition, all of the net operating loss carryforwards and research and development credits generated in years earlier than 201 4 and 201 3 , respectively, are still subject to Internal Revenue Service audit. The federal and California tax returns for the year ended December 31, 201 6 reflect research and development carryforwards of $5,430,000 and $5,317,000 , respectively. The Company has recognized additional deferred tax assets for federal and California research and development credits of $46,000 and $35,000 for the year ended December 31, 201 7 , respectively. As of December 31, 201 7 , our gross unrecognized tax benefits are approximately $10,828,000 which are attributable to research and development credit carryforwards . A reconciliation of the change in the Company’s unrecognized tax benefits is as follows:     (in thousands) Federal Tax State Tax Total  Balance at December 31, 2015 $ 5,335 $ 5,246 $ 10,581  Increase in tax position during 2016 95 71 166  Decrease due to expirations - - -  Balance at December 31, 2016 $ 5,430 $ 5,317 $ 10,747  Increase in tax position during 2017 46 35 81  Decrease due to expirations - - -  Balance at December 31, 2017 $ 5,476 $ 5,352 $ 10,828  The increase for the year ended December 31, 201 7 relates to a position taken in the current year. The increase for the year ended December 31, 201 6 is related to tax positions taken during 201 6 and prior years. If the $11,000,000 of unrecognized income tax benefit is recognized, approximately $11 ,000,000 would impact the effective tax rate in the period in which each of the benefits is recognized. We do not expect our unrecognized tax benefits to change significantly over the next 12 months. We recognize interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the consolidated statement of operations and comprehensive loss. We have not recorded any interest or penalties as a result of uncertain tax positions as of December 31, 201 7 and 201 6 . Accrued interest and penalties would be included within the related liability in the consolidated balance sheet.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 11: Related Party Transactions On December 18, 2017, the Company entered into a consulting agreement for a term of up to five months with the Company’s former Senior Vice President, Finance and Chief Accounting Officer. Pursuant to the terms of the consulting agreement, the consultant is providing accounting and finance services related to the transition of financial leadership . The Company will pay $150 per hour for such consulting services. The consultant will also remain eligible for payout under the Company’s 2017 Corporate Incentive Plan if he satisfactorily meets certain performance obligations as outlined in the consulting agreement. On January 18, 201 6 , the Company entered into a consulting agreement with a member of Vermillion’s Board of Directors. Pursuant to the terms of the consulting agreement, the consultant provide d consulting services regarding business strategies and operational plans and was paid $375 per hour or a minimum of $51,750 for the period up to the expiration of the agreement on March 31, 2016. During the year ended December 31, 2016, the consultant was paid $52,000 for services provided pursuant to the consulting agreement. 

Basis Of Presentation And Sum19

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Policy)	12 Months Ended
	Dec. 31, 2017
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies [Abstract]
Organization	Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells the OVA1™ and Overa™ risk of malignancy tests for ovarian cancer (“OVA1” and “Overa”). Until August 2015, the Company distributed OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”) (see Note 3). Since August 2015, the Company has distributed all tests through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”). The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which was formed in April 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. ASPiRA IVD was built around a core of laboratory expertise and a United States Food and Drug Administration (“FDA”)-compliant quality system, and strives to deliver accurate and reliable results to its third-party customers suitable for FDA submission.
Liquidity	Liquidity As discussed in Note 6, on March 22, 2016, the Company entered into a loan agreement , as amended (the “Loan Agreement”) , pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (“DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty. On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. Aggregate gross proceeds of the private placement were approximately $5,597,000 ( approximately $5,127,000 net of transaction costs) . The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share. The warrants expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period . In December 2014, the Company issued warrants to purchase up to an aggregate of 4,166,659 shares of Vermillion common stock at an exercise price of $2.00 per share in conjunction with a December 2014 private placement of Vermillion common stock. The warrants would have expire d by their original terms on December 23, 2017. On August 31, 2017, certain holders exercised warrants to purchase 3,796,818 shares of Vermillion common stock in consideration for the Company agreeing to reduce the exercise price to $1.00 per share of Vermillion common stock. The Company issued 3,796,818 shares of Vermillion common stock and received $3,796,818 in aggregate gross proceeds (approximately $3,576,000 net of transaction costs). The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $396,053,000 at December 31, 2017. The Company expects to incur a net loss in 2018 as well. The Company’s management believes that successful achievement of the business objectives will require additional financing. The Company expects to raise capital through a variety of sources, which may include the exercise of common stock warrants, public and private equity offerings, debt financing, collaborations, licensing arrangements, grants and government funding and strategic alliances. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the business, results of operations and financial condition. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Management expects cash from product and ASPiRA IVD sales to be the Company’s only material, recurring source of cash in 2018. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties.
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation
Use Of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates. 
Cash And Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.
Fair Value Measurement	Fair Value Measurement Accounting Standards Codification (“ASC”) Topic 820, Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.
Concentration Of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 , but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.
Accounts Receivable	Accounts receivable Virtually all accounts receivable are derived from sales made to customers located in North America. The Company performs ongoing credit evaluations of its customer’s financial condition and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable. Accounts receivable at December 31, 2017 was from 20 customers. Accounts receivable at December 31, 2016 was from 16 customers. 
Property And Equipment	Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized. 
Revenue Recognition	 Revenue Recognition Product Revenue: The Company has adopted ASC 954-605, Health Care Entities—Revenue Recognition, as revenue from laboratory services has become significant to the Company . The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1 and Overa tests may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.  Estimates of amounts that the Company will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the patient’s health plan. Some payers may not cover the OVA1 or Overa test as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.  Service Revenue: The Company’s service revenue is generated by performing IVD trial services for third-party customers. In accordance with SEC Staff Accounting Bulletin Topic 13, service revenue is recognized when the following revenue recognition criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. 
Research And Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established. 
Patent Costs	Patent Costs Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately $258,000 and $308,000 for the years ended December 31, 2017 and 2016, respectively. 
Stock-Based Compensation	Stock-Based Compensation The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Amended and Restated 2010 Stock Incentive Plan, as amended (the “2010 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. The Company uses the straight line method to amortize the fair value over the vesting period of the award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment. The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility is estimated using Company historical volatility in deriving the expected volatility assumption . The Company made an assessment that Company historic volatility is most representative of future stock price trends. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of the Company’s common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company uses the straight-line method to amortize the fair value over the vesting period of the award. The Company records stock-based compensation net of estimated forfeitures . The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options is recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another. 
Contingencies	Contingencies The Company accounts for contingencies in accordance with ASC 450 Contingencies ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.
Income Taxes	  Income Taxes The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. ASC Topic 740, Accounting for Uncertainty in Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets. New tax legislation, commonly referred to as the Tax Cuts and Jobs Act (H.R. 1), was enacted on December 22, 2017. ASC740, Accounting for Income Taxes , requires companies to recognize the effect of tax law changes in the period of enactment even though the effective date for most provisions is for tax years beginning after December 31, 2017. Since our federal deferred tax asset was fully offset by a valuation allowance, the reduction in the U.S. corporate income tax rate to 21% did not materially affect our financial statements. Significant provisions that are not yet effective but may impact income taxes in future years include: the repeal of the corporate Alternative Minimum Tax, the limitation on the current deductibility of net interest expense in excess of 30% of adjusted taxable income for levered balance sheets, a limitation on utilization of net operating losses generated after tax year 2017 to 80% of taxable income, the unlimited carryforward of net operating losses generated after tax year 2017, temporary 100% expensing of certain business assets, additional limitations on certain general and administrative expenses, and changes in determining the excessive compensation limitation. Currently, we do not anticipate paying cash federal income taxes in the near term due to any of the legislative changes, primarily due to the availability of our net operating loss carryforwards. Future interpretations relating to the recently enacted U.S. federal income tax legislation which vary from our current interpretation and possible changes to state tax laws in response to the recently enacted federal legislation may have a significant effect on this projection. 
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments Financial instrument s include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt are at cost, which approximates fair value due to the short maturity of those instruments. 
Segment Reporting	Segment Reporting The Company operates one reportable segment.

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property And Equipment [Abstract]
Components Of Property And Equipment	   December 31,  (in thousands) 2017 2016  Machinery and equipment $ 1,400 $ 1,381  Demonstration equipment 39 39  Computer equipment and software 1,055 1,029  Furniture and fixtures 120 127  Leasehold improvements 706 704  Gross property and equipment 3,320 3,280  Accumulated depreciation and amortization (2,139) (1,369)  Property and equipment, net $ 1,181 $ 1,911 

Accurued Liabilities (Tables)

Accurued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities [Abstract]
Components Of Accrued Liabilities	   December 31,  (in thousands) 2017 2016  Payroll and benefits related expenses $ 867 $ 541  Collaboration and research agreements expenses 358 414  Professional services 216 217  Tax-related liabilities - 4  Other accrued liabilities 209 288  Total accrued liabilities $ 1,650 $ 1,464 

Commitments, Contingencies An22

Commitments, Contingencies And Debt (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments, Contingencies And Debt [Abstract]
Summary Of Commitments And Contigencies	   Payments Due by Period  (in thousands) Total Less Than 1 Year 1-3 Years 3-5 Years More Than 5 Years  Operating Leases $ 574 $ 258 $ 261 $ 55 $ -  Capital Leases 20 20 - - -  Debt Obligations 1,860 221 442 442 755  Total Contractual Obligations $ 2,454 $ 499 $ 703 $ 497 $ 755   

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2017
Common Stock [Abstract]
Schedule Of Warrants Outstanding	   Exercise Price Number of Shares Outstanding under Warrant  Issuance Date Expiration Date per Share December 31, 2017 December 31, 2016  December 23, 2014 December 23, 2017 $ 2.00 - 4,166,659  February 17, 2017 February 17, 2022 $ 1.80 2,810,338 -  2,810,338 4,166,659  

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Loss Per Share [Abstract]
Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share	   Loss Shares Per Share  (In thousands, except per share data) (Numerator) (Denominator) Amount  Year ended December 31, 2016:  Net loss available to common shareholders - basic $ (14,968) 52,197,969 $ (0.29)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (14,968) 52,197,969 $ (0.29)   Year ended December 31, 2017:  Net loss $ (10,497)  Deemed dividend on warrant repricing (942)  Net loss available to common shareholders - basic (11,439) 56,943,596 $ (0.20)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (11,439) 56,943,596 $ (0.20)  
Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation	   Year Ended December 31,  2017 2016  Stock options 4,219,568 3,451,073  Stock warrants 2,810,338 4,166,659  Unvested restricted stock awards 1,704 7,752  Potential common shares 7,031,610 7,625,484 

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Employee Benefit Plans [Abstract]
Activity Related to Shares Available for Grant Under the 2000 Plan and 2010 Plan	   2000 Stock Plan 2010 Stock Option Plan Total  Shares available at December 31, 2015 - 3,371,505 3,371,505  Options canceled 33,050 2,243,217 2,276,267  Reduction in shares reserved (33,050) - (33,050)  Options granted - (2,413,070) (2,413,070)  Restricted stock units granted - (211,892) (211,892)  Shares available at December 31, 2016 - 2,989,760 2,989,760  Options canceled 3,050 776,455 779,505  Reduction in shares reserved (3,050) - (3,050)  Options granted - (1,548,000) (1,548,000)  Restricted stock units granted - (163,582) (163,582)  Shares available at December 31, 2017 - 2,054,633 2,054,633  
Stock Option Activity Under 2000 Plan and 2010 Plan	   Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term  Options outstanding at December 31, 2015 3,317,811 $ 2.29 $ 91 8.24  Granted 2,413,070 1.33  Exercised (3,541) 1.30  Canceled (2,276,267) 2.21  Options outstanding at December 31, 2016 3,451,073 $ 1.70 $ 41 8.46  Granted 1,548,000 2.05  Exercised - -  Canceled (779,505) 1.51  Options outstanding at December 31, 2017 4,219,568 $ 1.86 $ 1,033 8.02   Shares exercisable:  December 31, 2017 1,855,662 $ 1.99 $ 427 7.06  Shares expected to vest:  December 31, 2017 1,938,403 $ 1.77 $ 606 8.77 
Range of Exercise Prices for Options Outstanding and Exercisable	   Exercise Price Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Life in Years Options Exercisable Weighted Average Exercise Price  $ 0.01 - $ 1.30 435,625 $ 0.99 8.74 188,489 $ 1.00  1.31 - 1.64 1,369,168 1.50 8.01 561,957 1.52  1.65 - 2.08 1,038,500 1.96 7.44 660,131 1.95  2.09 - 11.55 1,376,275 2.43 8.23 445,085 3.05   $ 0.01 - $ 11.55 4,219,568 $ 1.86 8.02 1,855,662 $ 1.99 
Fair Value of Options Vested	   (in thousands) Total Intrinsic Value of Options Exercised Total Fair Value of Vested Options  Year ended December 31, 2017 $ - $ 2,272  Year ended December 31, 2016 $ 1 $ 1,562 
Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan	   Year Ended December 31,  2017 2016  Dividend yield - % - %  Volatility 69 % 77 %  Risk-free interest rate 1.77 % 0.96 %  Expected lives (years) 4.0 4.0  Weighted average fair value $ 1.11 $ 0.77 
Allocation of Stock-Based Compensation Expense by Functional Area	   Year Ended December 31,  (in thousands) 2017 2016  Cost of sales $ 82 $ 93  Research and development 6 71  Sales and marketing 150 101  General and administrative 914 759  Total $ 1,152 $ 1,024 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Taxes [Abstract]
Components Of Deferred Tax Assets (Liabilities)	   Year Ended December 31,  (in thousands) 2017 2016  Deferred tax assets:  Net operating losses $ 17,768 $ 22,861  Amortization - R&D intangibles 3,091 5,327  Other 2,461 2,903  Total deferred tax assets 23,320 31,091  Valuation allowance (23,320) (31,091)  Deferred tax assets $ - $ -   Deferred tax liabilities:  Other $ - $ -  Deferred tax liabilities $ - $ -   Net deferred tax asset $ - $ - 
Reconciliation Of Statutory Federal Income Tax Rate	   Year Ended December 31,  2017 2016  Tax at federal statutory rate 34 % 34 %  State tax, net of federal benefit 1 1  Valuation allowance 74 291  Change in warrant valuation - -  Net operating loss and credit reduction due to section 382 limitations - (327)  Permanent items (2) (2)  Change in Federal Tax Rate (2017 Tax Reform) (111) -  Other 4 3  Effective income tax rate - % - % 
Reconciliation Of Change In Unrecognized Tax Benefits	   (in thousands) Federal Tax State Tax Total  Balance at December 31, 2015 $ 5,335 $ 5,246 $ 10,581  Increase in tax position during 2016 95 71 166  Decrease due to expirations - - -  Balance at December 31, 2016 $ 5,430 $ 5,317 $ 10,747  Increase in tax position during 2017 46 35 81  Decrease due to expirations - - -  Balance at December 31, 2017 $ 5,476 $ 5,352 $ 10,828 

Basis Of Presentation And Sum27

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Details)	Aug. 31, 2017USD ($)$ / sharesshares	Feb. 17, 2017USD ($)$ / sharesshares	Apr. 15, 2016USD ($)	Dec. 31, 2014$ / sharesshares	Dec. 31, 2018	Dec. 31, 2017USD ($)customersegment$ / sharesshares	Dec. 31, 2016USD ($)customer$ / sharesshares	Mar. 22, 2016USD ($)
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued | shares		3,747,125				60,036,017	52,328,492
Price per share | $ / shares		$ 1.40				$ 0.001	$ 0.001
Common stock issued in conjunction with exercise of warrants, net of issuance costs (in shares) | shares	3,796,818
Common stock issued in conjunction with exercise of warrants	$ 3,796,818
Common stock issued in conjunction with exercise of warrants, net of issuance costs	$ 3,576,000					$ 3,576,000
Issued a warrant to purchase common stock with a cost | $ / shares		$ 0.125
Proceeds From Issuance Of Private Placement		$ 5,597,000				$ 5,127,000
Net proceeds from issuance of private placement		$ 5,127,000
Warrants outstanding to purchase shares | shares		2,810,338				2,810,338	4,166,659
Exercise price of warrants | $ / shares	$ 1	$ 1.80		$ 2
DECD initial disbursement							$ 1,967,000
Warrants issued in connection with private placement | shares				4,166,659
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights | $ / shares	$ 1	$ 1.80		$ 2
Warrants exercised | shares	3,796,818
Accumulated deficit						$ (396,053,000)	$ (385,556,000)
Accounts receivable, number of customers | customer						20	16
Patent costs						$ 258,000	$ 308,000
Estimated annual effective rate						34.00%	34.00%
Alternative Minimum Tax Rate						30.00%
Number of reportable segments | segment						1
DECD [Member] | Line of Credit [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
DECD maximum borrowing capacity								$ 4,000,000
DECD initial disbursement			$ 2,000,000
DECD remaining borrowing capacity								$ 2,000,000
Scenario, Plan [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Estimated annual effective rate					21.00%
Alternative Minimum Tax Rate					80.00%
Temporary expensing of certain business assets, tax rate					100.00%
Minimum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Useful life						3 years
Maximum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Useful life						5 years

Recent Accounting Pronounceme28

Recent Accounting Pronouncements (Details) - Forecast [Member] - Accounting Standards Update 2014-09 [Member]	Jan. 01, 2018USD ($)
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adjustment	$ 400,000
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adjustment	$ 700,000

Property And Equipment (Narrati

Property And Equipment (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation expense for property and equipment	$ 786,000	$ 723,000
Accumulated amortization	2,139,000	1,369,000
Net book value	1,181,000	1,911,000
Assets Under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Accumulated amortization	193,000	116,000
Net book value	$ 39,000	$ 116,000

Property And Equipment (Compone

Property And Equipment (Components Of Property And Equipment) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 3,320	$ 3,280
Accumulated depreciation and amortization	(2,139)	(1,369)
Property and equipment, net	1,181	1,911
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,400	1,381
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	39	39
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,055	1,029
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	120	127
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 706	$ 704

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities [Abstract]
Payroll and benefits related expenses	$ 867	$ 541
Collaboration and research agreements expenses	358	414
Professional services	216	217
Tax-related liabilities		4
Other accrued liabilities	209	288
Total accrued liabilities	$ 1,650	$ 1,464

Commitments, Contingencies An32

Commitments, Contingencies And Debt (Narrative) (Details)	Apr. 15, 2016USD ($)	Apr. 30, 2015USD ($)	Dec. 31, 2017USD ($)employee	Dec. 31, 2016USD ($)	Mar. 22, 2016USD ($)
Commitments And Contingencies [Line Items]
DECD initial disbursement				$ 1,967,000
Operating leases rental expense			254,000	234,000
Accumulated amortization			2,139,000	1,369,000
Net book value			1,181,000	1,911,000
Research and development			837,000	2,172,000
Royalty expense			116,000	92,000
Austin, Texas facility [Member]
Commitments And Contingencies [Line Items]
Annual base rent			86,000
Annual estimated common area charges, taxes and insurance			$ 46,000
Lease expiration date			Jan. 31, 2019
Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Annual base rent			$ 32,000
Annual estimated common area charges, taxes and insurance			$ 95,000
Lease expiration date			Jun. 8, 2021
Johns Hopkins University School Of Medicine [Member]
Commitments And Contingencies [Line Items]
Research and development			$ 15,000	264,000
Percent of royalty paid			4.00%
Minimum royalty payment			$ 57,500
Assets Under Capital Leases [Member]
Commitments And Contingencies [Line Items]
Total initial payment		$ 125,000
Monthly payment for acquisition for equipment		$ 3,500
Number of payments for purchase production of assets			36 months
Accumulated amortization			$ 193,000	116,000
Net book value			$ 39,000	116,000
Line of Credit [Member] | DECD [Member]
Commitments And Contingencies [Line Items]
DECD maximum borrowing capacity					$ 4,000,000
Fixed rate per annum					2.00%
Amount eligible for forgiveness					$ 2,000,000
Job creation, number of employees | employee			40
Job creation, term			2 years
Debt, maturity term			10 years
Debt penalty percentage			5.00%
DECD initial disbursement	$ 2,000,000
DECD remaining borrowing capacity					$ 2,000,000
Balance of loan			$ 1,666,000	$ 1,849,000

Commitments, Contingencies An33

Commitments, Contingencies And Debt (Summary Of Commitments And Contigencies) (Details) $ in Thousands	Dec. 31, 2017USD ($)
Other Commitments [Line Items]
Total accrued liabilities	$ 2,454
Total accrued liabilities, Less Than 1 Year	499
Total accrued liabilities, 1-3 Years	703
Total accrued liabilities, 3-5 Years	497
Total accrued liabilities, More Than 5 Years	755
Operating Lease [Member]
Other Commitments [Line Items]
Total accrued liabilities	574
Total accrued liabilities, Less Than 1 Year	258
Total accrued liabilities, 1-3 Years	261
Total accrued liabilities, 3-5 Years	55
Total accrued liabilities, More Than 5 Years
Capital Leases [Member]
Other Commitments [Line Items]
Total accrued liabilities	20
Total accrued liabilities, Less Than 1 Year	20
Total accrued liabilities, 1-3 Years
Total accrued liabilities, 3-5 Years
Total accrued liabilities, More Than 5 Years
Debt Obligations [Member]
Other Commitments [Line Items]
Total accrued liabilities	1,860
Total accrued liabilities, Less Than 1 Year	221
Total accrued liabilities, 1-3 Years	442
Total accrued liabilities, 3-5 Years	442
Total accrued liabilities, More Than 5 Years	$ 755

Common Stock (Narrative) (Detai

Common Stock (Narrative) (Details) - USD ($)	Dec. 31, 2017	Aug. 31, 2017	Feb. 17, 2017	Dec. 31, 2016	Dec. 31, 2014
Common Stock [Abstract]
Common stock, shares issued	60,036,017		3,747,125	52,328,492
Price per share	$ 0.001		$ 1.40	$ 0.001
Issued a warrant to purchase common stock with a cost			$ 0.125
Warrants outstanding to purchase shares	2,810,338		2,810,338	4,166,659
Exercise price of warrants		$ 1	$ 1.80		$ 2
Fair value of warrants issued			$ 804,000
Common stock value	$ 60,000		$ 4,323,000	$ 52,000

Common Stock (Schedule Of Warra

Common Stock (Schedule Of Warrants Outstanding) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Aug. 31, 2017	Feb. 17, 2017	Dec. 31, 2016	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Exercise Price per Share		$ 1	$ 1.80		$ 2
Number of Shares Outstanding under Warrant	2,810,338		2,810,338	4,166,659
December 23, 2014 - December 23, 2017 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Dec. 23, 2014
Expiration Date	Dec. 23, 2017
Exercise Price per Share	$ 2
Number of Shares Outstanding under Warrant				4,166,659
February 17, 2017 - February 17, 2022 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Feb. 17, 2017
Expiration Date	Feb. 17, 2022
Exercise Price per Share	$ 1.80
Number of Shares Outstanding under Warrant	2,810,338

Loss Per Share (Reconciliation

Loss Per Share (Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Loss (Numerator)
Net loss	$ (10,497)	$ (14,968)
Deemed dividend on warrant repricing	942
Net loss attributable to common stockholders	(11,439)	(14,968)
Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards
Net loss available to common shareholder - diluted	$ (11,439)	$ (14,968)
Shares (Denominator)
Net loss available to common shareholders - basic	56,943,596	52,197,969
Net loss available to common shareholder - diluted	56,943,596	52,197,969
Per Share Amount
Net loss available to common shareholders - basic	$ (0.20)	$ (0.29)
Net loss available to common shareholder - diluted	$ (0.20)	$ (0.29)

Loss Per Share (Potential Share

Loss Per Share (Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation) (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	7,031,610	7,625,484
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	4,219,568	3,451,073
Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,810,338	4,166,659
Unvested Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,704	7,752

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narrative) (Details) - USD ($)	Jun. 18, 2015	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, exercised			3,541
Total unrecognized compensation cost related to nonvested stock option awards		$ 2,147,000
Weighted average period over which unrecognized cost expected to be recognized		2 years 6 months 22 days
401(k) Plan, percentage for compensation defer		90.00%
401 (k) contributions		$ 0	$ 0
2000 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vesting period		4 years
Stock options, expiration period		10 years
Stock options, exercised		0	0
Maximum common stock provides for issuance under stock plan		0
2000 Stock Plan [Member] | Statutory Stock Options | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grant price, percentage of fair market value of common stock		100.00%
2000 Stock Plan [Member] | Nonstatutory Stock Options | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grant price, percentage of fair market value of common stock		85.00%
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expiration period		10 years
Stock options, exercised		0	3,541
Maximum common stock provides for issuance under stock plan		8,122,983
Additional shares authorized	4,500,000
2010 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted share units		$ 281,000
Restricted share units granted		131,250
2010 Stock Incentive Plan [Member] | Restricted Stock [Member] | Board Of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted share units			$ 310,000
Restricted share units granted			197,727
2010 Stock Incentive Plan [Member] | Restricted Stock [Member] | Certain Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted share units		$ 54,000	$ 18,000
Restricted share units granted		32,332	14,165

Employee Benefit Plans (Activit

Employee Benefit Plans (Activity Related to Shares Available for Grant Under the 2000 Plan and 2010 Plan) (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available	2,989,760	3,371,505
Canceled	779,505	2,276,267
Reduction in shares reserved	(3,050)	(33,050)
Granted	(1,548,000)	(2,413,070)
Restricted stock units granted	(163,582)	(211,892)
Shares available at End of period	2,054,633	2,989,760
2000 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available
Canceled	3,050	33,050
Reduction in shares reserved	(3,050)	(33,050)
Granted
Restricted stock units granted
Shares available at End of period
2010 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available	2,989,760	3,371,505
Canceled	776,455	2,243,217
Reduction in shares reserved
Granted	(1,548,000)	(2,413,070)
Restricted stock units granted	(163,582)	(211,892)
Shares available at End of period	2,054,633	2,989,760

Employee Benefit Plans (Stock O

Employee Benefit Plans (Stock Option Activity Under 2000 Plan and 2010 Plan) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Shares
Options outstanding	3,451,073	3,317,811
Granted	1,548,000	2,413,070
Exercised		(3,541)
Canceled	(779,505)	(2,276,267)
Options outstanding	4,219,568	3,451,073	3,317,811
Shares exercisable	1,855,662
Shares expected to vest	1,938,403
Weighted Average Exercise Price
Opstions outstanding	$ 1.70	$ 2.29
Granted	2.05	1.33
Exercised		1.30
Canceled	1.51	2.21
Opstions outstanding	1.86	$ 1.70	$ 2.29
Shares exercisable	1.99
Shares expected to vest	$ 1.77
Aggregate Intrinsic Value
Options outstanding	$ 1,033	$ 41	$ 91
Shares exercisable	427
Shares expected to vest	$ 606
Weighted Average Remaining Contractual Term
Options outstanding	8 years 7 days	8 years 5 months 16 days	8 years 2 months 27 days
Shares exercisable	7 years 22 days
Shares expected to vest	8 years 9 months 7 days

Employee Benefit Plans (Range o

Employee Benefit Plans (Range of Exercise Prices for Options Outstanding and Exercisable) (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$ 0.01
Exercise Price Upper Range	$ 11.55
Options Outstanding | shares	4,219,568
Weighted Average Exercise Price	$ 1.86
Weighted Average Remaining life	8 years 7 days
Options Exercisable | shares	1,855,662
Weighted Average Exercise Price	$ 1.99
$0.01 - $1.30 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	0.01
Exercise Price Upper Range	$ 1.30
Options Outstanding | shares	435,625
Weighted Average Exercise Price	$ 0.99
Weighted Average Remaining life	8 years 8 months 27 days
Options Exercisable | shares	188,489
Weighted Average Exercise Price	$ 1
$1.31 - $1.64 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	1.31
Exercise Price Upper Range	$ 1.64
Options Outstanding | shares	1,369,168
Weighted Average Exercise Price	$ 1.50
Weighted Average Remaining life	8 years 4 days
Options Exercisable | shares	561,957
Weighted Average Exercise Price	$ 1.52
$1.65 - $2.08 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	1.65
Exercise Price Upper Range	$ 2.08
Options Outstanding | shares	1,038,500
Weighted Average Exercise Price	$ 1.96
Weighted Average Remaining life	7 years 5 months 9 days
Options Exercisable | shares	660,131
Weighted Average Exercise Price	$ 1.95
$2.09 - $11.55 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	2.09
Exercise Price Upper Range	$ 11.55
Options Outstanding | shares	1,376,275
Weighted Average Exercise Price	$ 2.43
Weighted Average Remaining life	8 years 2 months 23 days
Options Exercisable | shares	445,085
Weighted Average Exercise Price	$ 3.05

Employee Benefit Plans (Fair Va

Employee Benefit Plans (Fair Value of Options Vested) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Employee Benefit Plans [Abstract]
Total Intrinsic Value of Options Exercised		$ 1
Total Fair Value of Vested Options	$ 2,272	$ 1,562

Employee Benefit Plans (Assumpt

Employee Benefit Plans (Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Employee Benefit Plans [Abstract]
Dividend yield
Volatility	69.00%	77.00%
Risk-free interest rate	1.77%	0.96%
Expected lives (years)	4 years	4 years
Weighted average fair value	$ 1.11	$ 0.77

Employee Benefit Plans (Allocat

Employee Benefit Plans (Allocation Of Employee Stock-Based Compensation Expense By Functional Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 136	$ 115
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	9	71
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	160	108
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,134	885
Employee Stock-based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,152	1,024
Employee Stock-based Compensation [Member] | Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	82	93
Employee Stock-based Compensation [Member] | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	6	71
Employee Stock-based Compensation [Member] | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	150	101
Employee Stock-based Compensation [Member] | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 914	$ 759

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Income tax benefit (expense)		$ 0	$ 0
Operating loss, net carryforwards expiration amount		12,000,000
additional deferred tax assets		81,000	166,000
Valuation allowance		23,320,000	$ 31,091,000
Decrease in valuation allowance		$ 8,000,000
U.S. federal corporate tax		35.00%
Estimated annual effective rate		34.00%	34.00%
Gross unrecognized tax benefits		$ 10,828,000	$ 10,747,000	$ 10,581,000
Total Unrecognized income tax benefit, affecting effective tax rate if recognized			11,000,000
Accrued interest and penalties		0	0
Research And Development Carryforward [Member]
Income Taxes [Line Items]
Gross unrecognized tax benefits		10,828,000
Federal Tax [Member]
Income Taxes [Line Items]
Operating loss carryforwards		71,000,000	59,000,000
additional deferred tax assets		46,000	95,000
Gross unrecognized tax benefits		5,476,000	5,430,000	5,335,000
Federal Tax [Member] | Research And Development Carryforward [Member]
Income Taxes [Line Items]
additional deferred tax assets		46,000
Gross unrecognized tax benefits			5,430,000
State Tax [Member]
Income Taxes [Line Items]
Operating loss carryforwards		173,000,000	167,000,000
additional deferred tax assets		35,000	71,000
Gross unrecognized tax benefits		5,352,000	5,317,000	$ 5,246,000
State Tax [Member] | Research And Development Carryforward [Member]
Income Taxes [Line Items]
additional deferred tax assets		$ 35,000
Gross unrecognized tax benefits			$ 5,317,000
Minimum [Member] | Federal Tax [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date		Dec. 31, 2027
Minimum [Member] | State Tax [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date		Dec. 31, 2018
Scenario, Plan [Member]
Income Taxes [Line Items]
U.S. federal corporate tax	21.00%
Estimated annual effective rate	21.00%

Income Taxes (Components Of Def

Income Taxes (Components Of Deferred Tax Assets (Liabilities)) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating losses	$ 17,768	$ 22,861
Amortization - R&D intangibles	3,091	5,327
Other	2,461	2,903
Total deferred tax assets	23,320	31,091
Valuation allowance	(23,320)	(31,091)
Deferred tax assets
Deferred tax liabilities:
Other
Deferred tax liabilities
Net deferred tax asset

Income Taxes (Reconciliation Of

Income Taxes (Reconciliation Of Statutory Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Tax at federal statutory rate	34.00%	34.00%
State tax, net of federal benefit	1.00%	1.00%
Valuation allowance	74.00%	291.00%
Change in warrant valuation
Net operating loss and credit reduction due to section 382 limitations		(327.00%)
Permanent items	(2.00%)	(2.00%)
Change in Federal Tax Rate (2017 Tax Reform)	(111.00%)
Other	4.00%	3.00%
Effective Income Tax Rate Reconciliation, Percent, Total

Income Taxes (Reconciliation 48

Income Taxes (Reconciliation Of Change In Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Contingency [Line Items]
Beginning Balance	$ 10,747	$ 10,581
Increase in tax position	81	166
Decrease due to expirations
Ending Balance	10,828	10,747
Federal Tax [Member]
Income Tax Contingency [Line Items]
Beginning Balance	5,430	5,335
Increase in tax position	46	95
Decrease due to expirations
Ending Balance	5,476	5,430
State Tax [Member]
Income Tax Contingency [Line Items]
Beginning Balance	5,317	5,246
Increase in tax position	35	71
Decrease due to expirations
Ending Balance	$ 5,352	$ 5,317

Related Party Transactions (Det

Related Party Transactions (Details)	Dec. 18, 2017$ / H	Jan. 18, 2016USD ($)$ / H	Dec. 31, 2017	Dec. 31, 2016USD ($)
Director [Member]
Related Party Transaction [Line Items]
Consulting agreement fee per hour | $ / H		375
Consulting service expenses | $				$ 52,000
Former Senior Vice President, Finance And Chief Accounting Officer [Member]
Related Party Transaction [Line Items]
Term of consulting agreement			5 years
Consulting agreement fee per hour | $ / H	150
Minimum [Member] | Director [Member]
Related Party Transaction [Line Items]
Consulting agreement payable | $		$ 51,750